(range 4.7-94.0), 39 (15.4%) patients died and 47 (30.5%) patients experienced recurrence and the estimated DFS and OS at 3 years was 82.8% and 90.1%, respectively. In the univariate analysis, oxaliplatin chemotherapy was not significantly associated with DFS (p ¼ 0.457) and OS (p ¼ 0.147). In the multivariate analysis, the addition of oxaliplatin showed no prognostic significance on DFS (p ¼ 0.073) and OS (p ¼ 0.594). Conclusions: In conclusion, oxaliplatin-containing adjuvant chemotherapy was not found to have a significant effect on survival for stage III CC patients with only PLN. Accordingly, the current study can provide a novel strategy for subgroups with limited LNs distribution, considering that the state of the LN distribution is a critical factor for therapeutic success. Legal entity responsible for the study: Jong Gwang Kim. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Background: Fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer (CRC) is associated with a reduction of recurrence in only 25% of patients (pts) with stage III disease. The aim of this study was to investigate thymidylate synthase (TYMS) gene polymorphisms, KRAS and BRAF as possible factors affecting therapeutic outcome in pts with stage III CRC. Methods: Formalin-fixed paraffin-embedded tissues of 130 consecutive pts treated with FABC between 2005-2007 were analysed with PCR for the detection of TYMS polymorphisms, mKRAS and mBRAF. Patients were classified into three groups of 5'UTR TYMS polymorphisms according to the predicted expression profile (high, medium and low). Based on the presence or absence of the 3'UTR polymorphism ins/ LOH pts were allocated into two groups (high and low risk). Cox regression models examined factors associated with survival outcome. Results: The 5-year DFS and OS rate was 61.6% and 73.9% respectively. Patients who had tumors with 5'UTR polymorphisms of intermediate TYMS expression profile (2RG/3RG, 2RG/LOH, 3RC/LOH) when compared to those with low (2RG/2RG, 2RG/ 3RC, 3RC/3RC) or high expression (3RG/3RG, 3RG/LOH, 3RG/3RC) had lower risk for relapse (HR 0.320, p ¼ 0.02 and HR 0.343, p ¼ 0.013 respectively) and death (HR 0.368, p ¼ 0.031 and HR 0.394, p ¼ 0.029 respectively). The 3'UTR polymorphism ins/ LOH was independently associated with increased risk for disease recurrence (p ¼ 0.001) and death (p ¼ 0.005). Presence of mBRAF (3.8% pts) was associated with an increased risk of death (HR 4.500, p ¼ 0.022), whereas mKRAS (39% of pts) was not found to correlate with survival. Conclusions: The group of TYMS polymorphisms 2RG/3RG, 2RG/LOH, 3RC/LOH, the absence of ins/LOH and absence of mBRAF were associated with better prognosis of pts with early stage CRC. Mutated KRAS was not found to affect relapse or risk of death in the adjuvant setting. Further prospective studies investigating the role of TYMS polymorphisms and mBRAF are warranted to identify pts who could benefit from 5FU-based cytotoxic chemotherapy. Legal entity responsible for the study: Anna Koumarianou. Funding: National and Kapodistrian University of Athens. Disclosure: All authors have declared no conflicts of interest. Background: Inactivation of MLH1 due to promoter hypermethylation strongly suggests a sporadic origin, and nearly half sporadic colorectal cancer patients harbor BRAF mutation, providing exclusion criteria for Lynch syndrome (LS). However, there was little evidence from Chinese population. The aim of this study was to compare the utility of two tests, and explore the possibility of substituting BRAF immunohistochemical staining (IHC) for real-time PCR. Methods: We reviewed MMR expression status of consecutive patients who had undergone surgery for colorectal cancer between 2012.1.1 and 2014.12.30 in Chinese National Cancer Center. Among 317 patients who were identified as dMMR, 170 patients with MLH1 immunoloss were taken into final analysis. MLH1 methylation status was evaluated by MS-PCR(methylation -specific PCR) ,BRAF mutation was tested by IHC and real-time PCR. Results: 52.9%patients display MLH1 promoter hypermethylation. As for BRAF status, the mutation rate tested by IHC and real-time PCR was 14.1% and17.1%, respectively, and the concordance rate was 92.1%. BRAF mutation did better on ruling out patients whose relatives had CRC history. Although patients who had unmethylated CRCs had a notably stronger family history of CRC, there were still 13.3% patients in the hypermethylation group having family history of CRC, indicating a likelihood of LS. 
